Ajo LP bought a new stake in shares of Exactech, Inc. (NASDAQ:EXAC) during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 16,220 shares of the medical equipment provider’s stock, valued at approximately $483,000. Ajo LP owned about 0.11% of Exactech as of its most recent filing with the SEC.
Other large investors also recently made changes to their positions in the company. Bank of Montreal Can acquired a new stake in Exactech during the 2nd quarter valued at $134,000. Russell Investments Group Ltd. grew its holdings in Exactech by 13.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 47,118 shares of the medical equipment provider’s stock valued at $1,405,000 after buying an additional 5,485 shares during the last quarter. Schwab Charles Investment Management Inc. grew its holdings in Exactech by 14.3% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 53,918 shares of the medical equipment provider’s stock valued at $1,359,000 after buying an additional 6,742 shares during the last quarter. Teton Advisors Inc. grew its holdings in Exactech by 7.7% during the 2nd quarter. Teton Advisors Inc. now owns 250,373 shares of the medical equipment provider’s stock valued at $7,461,000 after buying an additional 17,900 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in Exactech by 7.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 36,617 shares of the medical equipment provider’s stock valued at $923,000 after buying an additional 2,612 shares during the last quarter. Hedge funds and other institutional investors own 64.58% of the company’s stock.
EXAC has been the topic of a number of analyst reports. BidaskClub cut Exactech from a “hold” rating to a “sell” rating in a report on Monday, July 31st. Gabelli reiterated a “buy” rating on shares of Exactech in a report on Monday, July 31st.
In other Exactech news, Director Fern Watts sold 1,013 shares of Exactech stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $29.04, for a total value of $29,417.52. Following the transaction, the director now owns 4,727 shares in the company, valued at $137,272.08. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders own 28.30% of the company’s stock.
Shares of Exactech, Inc. (EXAC) opened at 31.25 on Friday. The firm’s 50-day moving average price is $29.72 and its 200-day moving average price is $29.00. The firm has a market cap of $448.38 million, a PE ratio of 600.96 and a beta of 1.02. Exactech, Inc. has a one year low of $22.20 and a one year high of $31.90.
Exactech (NASDAQ:EXAC) last posted its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.33 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.33. The firm had revenue of $67.30 million for the quarter, compared to analyst estimates of $67.75 million. Exactech had a net margin of 0.30% and a return on equity of 7.39%. The firm’s quarterly revenue was up 1.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.31 earnings per share. Equities research analysts expect that Exactech, Inc. will post $1.29 earnings per share for the current fiscal year.
Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.
Receive News & Ratings for Exactech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.